JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Jasper Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.48−0.00 (-0.52%)
Close on Oct 19, 2026
- Market cap
- $13.70M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
36.1%
12M of 33M shares
Institutional holders
45
3 new, 16 sold out
Net institutional buying
-4M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Venkataraman Balaji | 3,363,347 | 9.90% | 13G (passive) | Aug 17, 2026 |
| Velan Capital Investment Management LP | 3,349,547 | 9.88% | 13D (active) amendment | Jul 16, 2026 |
| Velan Capital Management LLC | 2,668,395 | 9.60% | 13D (active) amendment | Sep 19, 2025 |
| T. Rowe Price Investment Management, Inc. | 2,057,612 | 7.10% | 13G (passive) | Sep 30, 2025 |
| Israel A. Englander | 1,629,013 | 5.80% | 13G (passive) | Feb 18, 2026 |
| Soleus GP LLC | 1,494,420 | 9.96% | 13G (passive) amendment | Dec 31, 2024 |
| Anders Hove | 1,486,492 | 5.30% | 13G (passive) amendment | Jan 23, 2026 |
| Guy Levy | 1,343,665 | 9.00% | 13G (passive) amendment | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of JSPR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 2,668,395 | 8.02% | $1.12M | – | 0.68% |
| Acorn Capital Advisors, LLC | 1,438,159 | 4.32% | $604.03K | +26,667 | 0.16% |
| Kingdon Capital Management, L.L.C. | 1,352,106 | 4.06% | $569.24K | – | 0.06% |
| Vanguard Capital Management LLC | 1,172,021 | 3.52% | $493.42K | −576 | 0.00% |
| Rock Springs Capital Management LP | 1,100,726 | 3.31% | $463.41K | – | 0.02% |
| Carlyle Group Inc. | 1,066,189 | 3.20% | $448.87K | – | 0.00% |
| Gsa Capital Partners Llp | 534,697 | 1.61% | $225 | +515,613 | 0.01% |
| Millennium Management LLC | 486,933 | 1.46% | $205.00K | −1,130,598 | 0.00% |
| Lion Point Capital, LP | 465,000 | 1.40% | $195.77K | – | 0.94% |
| Geode Capital Management, LLC | 263,808 | 0.79% | $111.09K | −53,869 | 0.00% |
| Renaissance Technologies LLC | 237,900 | 0.71% | $100.16K | +60,400 | 0.00% |
| BlackRock, Inc. | 169,627 | 0.51% | $71.41K | −72,434 | 0.00% |
| Vanguard Fiduciary Trust Co | 149,943 | 0.45% | $63.13K | – | 0.00% |
| ADAR1 Capital Management, LLC | 140,000 | 0.42% | $58.94K | – | 0.00% |
| Quarry LP | 131,529 | 0.40% | $55.37K | – | 0.00% |
| Jane Street Group, LLC | 101,743 | 0.31% | $42.83K | +80,328 | 0.00% |
| UBS Group AG | 58,759 | 0.18% | $24.74K | −22,358 | 0.00% |
| Jain Global LLC | 51,185 | 0.15% | $21.55K | +33,163 | 0.00% |
| Osaic Holdings, Inc. | 45,850 | 0.14% | $19.30K | +5,000 | 0.00% |
| State Street Corp | 44,699 | 0.13% | $18.82K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 45 | 12M | 36.1% | 3 / 9 | 14 / 16 | 1M | 5M |
| Q1 2026 | 58 | 16M | 47.5% | 13 / 15 | 13 / 9 | 4M | 7M |
| Q4 2025 | 55 | 20M | 58.9% | 11 / 23 | 11 / 15 | 6M | 6M |
| Q3 2025 | 60 | 20M | 60.6% | 15 / 16 | 19 / 20 | 10M | 2M |
| Q2 2025 | 65 | 13M | 37.7% | 17 / 17 | 17 / 20 | 1M | 2M |
| Q1 2025 | 68 | 13M | 39.2% | 13 / 20 | 23 / 30 | 2M | 4M |
| Q4 2024 | 87 | 16M | 47.0% | 20 / 32 | 16 / 14 | 3M | 2M |
| Q3 2024 | 81 | 15M | 44.2% | 25 / 22 | 20 / 12 | 3M | 2M |
| Q2 2024 | 69 | 15M | 43.8% | 26 / 16 | 12 / 18 | 2M | 1M |
| Q1 2024 | 61 | 13M | 40.2% | 60 / 0 | 1 / 0 | 13M | 0M |
| Q4 2023 | 1 | 0M | 1.5% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of JSPR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 833,391 | 2.50% | $350.86K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 312,032 | 0.94% | $131.37K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 153,206 | 0.46% | $127.01K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 49,896 | 0.15% | $41.36K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 34,109 | 0.10% | $28.28K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 26,598 | 0.08% | $11.20K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 9,659 | 0.03% | $8.01K | 0.00% | May 31, 2026 |
| Knights of Columbus U.S. ALL CAP INDEX FUND | 155 | 0.00% | $98 | 0.00% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -1,800 | -0.01% | -$758 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jeetinder Singh Mahal | CEO and President, Director | 25,009 | 0.08% | Feb 10, 2026 |
| Ron Martell | President, CEO and Director | 74,118 | 0.22% | Jan 5, 2026 |
| Greg Keenan | Chief Medical Officer | – | – | Jul 23, 2026 |
| Matthew E. Ros | Chief Operating Officer | – | – | Jul 22, 2026 |
| Wenru Song | EVP, Head of R&D | 3,150 | 0.01% | Jul 22, 2026 |
| Herb Cross | Chief Financial Officer | – | – | Jan 5, 2026 |
| Edwin Jonathan Tucker | Chief Medical Officer | 400 | 0.00% | Jun 6, 2025 |
| Kurt Von Emster | Director | 5,649,733 | 16.98% | Aug 4, 2026 |
| Patrick J. Crutcher | Director | 518,331 | 1.56% | Aug 4, 2026 |
| Thomas G. Wiggans | Director | 46,000 | 0.14% | Aug 4, 2026 |
| Judith Anne Shizuru | Director | 156,901 | 0.47% | Aug 4, 2026 |
| Svetlana Lucas | Director | 20,000 | 0.06% | Aug 4, 2026 |
| Chris Nolet | Director | 32,500 | 0.10% | Jul 3, 2025 |
| Scott C. Brun | Director | – | – | Jul 3, 2025 |
| Vishal Kapoor | Director | 43,750 | 0.13% | Jul 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Svetlana Lucas Director | Sep 22, 2025 | Buy | +20,000 | $2.43 | $48.60K | 20,000 |
| Judith Anne Shizuru Director | Sep 22, 2025 | Buy | +41,000 | $2.43 | $99.63K | 156,901 |
| Ron Martell President and CEO, Director | Sep 22, 2025 | Buy | +41,000 | $2.43 | $99.63K | 74,118 |
| Thomas G. Wiggans Director | Sep 22, 2025 | Buy | +41,000 | $2.43 | $99.63K | 41,000 |
| Jeetinder Singh Mahal Chief Operating Officer | Dec 12, 2024 | Sale(10b5-1 plan) | −900 | $22.11 | $19.90K | 25,009 |
| Jeetinder Singh Mahal Chief Operating Officer | Dec 12, 2024 | Option exercise | +900 | $7.10 | $6.39K | 25,909 |
| Jeetinder Singh Mahal Chief Operating Officer | Sep 12, 2024 | Option exercise | +900 | $7.10 | $6.39K | 25,909 |
| Jeetinder Singh Mahal Chief Operating Officer | Sep 12, 2024 | Sale(10b5-1 plan) | −900 | $21.23 | $19.11K | 25,009 |
| Jeetinder Singh Mahal Chief Operating Officer | Jun 12, 2024 | Option exercise | +900 | $7.10 | $6.39K | 25,909 |
| Jeetinder Singh Mahal Chief Operating Officer | Jun 12, 2024 | Sale(10b5-1 plan) | −900 | $24.16 | $21.74K | 25,009 |
| Edwin Jonathan Tucker Chief Medical Officer | Jun 7, 2024 | Award | +400 | $4.17 | $1.67K | 400 |
| Jeetinder Singh Mahal Chief Operating Officer | Mar 12, 2024 | Option exercise | +900 | $7.10 | $6.39K | 25,909 |
| Jeetinder Singh Mahal Chief Operating Officer | Mar 12, 2024 | Sale(10b5-1 plan) | −900 | $26.44 | $23.80K | 25,009 |
| LLP Abingworth 10% owner | Feb 8, 2024 | Buy | +190,000 | $12.95 | $2.46M | 1,066,189 |
| Balaji Venkataraman 10% owner | Feb 8, 2024 | Buy | +350,000 | $12.95 | $4.53M | 1,188,500 |
| Thomas G. Wiggans Director | Nov 28, 2023 | Buy | +10,000 | $0.65 | $6.50K | 50,000 |
| Thomas G. Wiggans Director | Nov 21, 2023 | Buy | +10,000 | $0.64 | $6.40K | 40,000 |
| Thomas G. Wiggans Director | Nov 20, 2023 | Buy | +10,000 | $0.63 | $6.30K | 30,000 |
| Thomas G. Wiggans Director | Nov 17, 2023 | Buy | +10,000 | $0.60 | $6.00K | 20,000 |
| Thomas G. Wiggans Director | Nov 16, 2023 | Buy | +10,000 | $0.60 | $6.00K | 10,000 |
| William Lis Director | Oct 13, 2023 | Sale(10b5-1 plan) | −7,965 | $0.85 | $6.77K | 53,521 |
| Jeetinder Singh Mahal Chief Operating Officer | Oct 12, 2023 | Tax withholding | −37,126 | $0.85 | $31.56K | 250,097 |
| Ron Martell President, CEO & Director | Oct 12, 2023 | Tax withholding | −87,531 | $0.85 | $74.40K | 331,188 |
| Jeetinder Singh Mahal See Remarks | Jun 13, 2023 | Option exercise | +9,000 | $0.71 | $6.39K | 296,223 |
| Jeetinder Singh Mahal See Remarks | Jun 13, 2023 | Sale(10b5-1 plan) | −9,000 | $1.66 | $14.94K | 287,223 |
| Anna Louise French Director | Apr 14, 2023 | Sale | −7,000 | $1.48 | $10.36K | 23,750 |
| William Lis Director | Apr 13, 2023 | Sale | −8,500 | $1.44 | $12.24K | 61,486 |
| Kurt Von Emster Director | Apr 13, 2023 | Sale | −9,075 | $1.49 | $13.52K | 21,175 |
| Ron Martell President, CEO and Director | Apr 12, 2023 | Tax withholding | −87,531 | $1.46 | $127.80K | 418,719 |
| Jeetinder Singh Mahal See Remarks | Apr 12, 2023 | Tax withholding | −37,126 | $1.46 | $54.20K | 287,223 |
| Qiming U.S. Healthcare GP II, LLC 10% owner | Jan 27, 2023 | Buy | +2,666,666 | $1.50 | $4.00M | 8,519,648 |
| TC Group, LLC 10% owner | Jan 27, 2023 | Buy | +3,133,333 | $1.50 | $4.70M | 8,761,891 |
| Finance Ltd Roche 10% owner | Jan 25, 2023 | Sale | −75,000 | $1.89 | $141.75K | 4,549,606 |
| Judith Anne Shizuru Director | Oct 12, 2022 | Award | +29,500 | – | – | 1,159,012 |
| Kurt Von Emster Director | Oct 12, 2022 | Award | +30,250 | – | – | 30,250 |
| Jeetinder Singh Mahal See Remarks | Oct 12, 2022 | Award | +214,722 | – | – | 324,349 |
| William Lis Director | Oct 12, 2022 | Award | +29,500 | – | – | 69,986 |
| Lawrence Otto Klein Director | Oct 12, 2022 | Award | +24,500 | – | – | 24,500 |
| Ron Martell President, CEO and Director | Oct 12, 2022 | Award | +506,250 | – | – | 506,250 |
| Anna Louise French Director | Oct 12, 2022 | Award | +30,750 | – | – | 30,750 |
| Chris Nolet Director | Oct 12, 2022 | Award | +32,500 | – | – | 32,500 |
| William Lis Director | Jun 27, 2022 | Sale(10b5-1 plan) | −24,743 | $2.08 | $51.47K | 40,486 |
| William Lis Director | Jun 24, 2022 | Sale(10b5-1 plan) | −24,743 | $2.02 | $49.98K | 65,229 |
| William Lis See Remarks, Director | Mar 21, 2022 | Award | +89,972 | – | – | 89,972 |
| Howard I. Hoffen – | Sep 24, 2021 | Option exercise | +2,300,000 | – | – | 2,300,000 |
| Kenneth F. Clifford – | Sep 24, 2021 | Option exercise | +2,300,000 | – | – | 2,300,000 |
| Healthcare Holdings LLC Amplitude 10% owner | Sep 24, 2021 | Option exercise | +2,300,000 | – | – | 2,300,000 |
| Balaji Venkataraman – | Sep 24, 2021 | Option exercise | +2,300,000 | – | – | 2,300,000 |
| Paul J. Glazer 10% owner | Apr 23, 2021 | Sale | −151,719 | $9.92 | $1.51M | 895,059 |
| Paul J. Glazer 10% owner | Apr 21, 2021 | Sale | −1,164 | $9.92 | $11.55K | 1,046,778 |
| Glazer Capital, Llc 10% owner | Apr 19, 2021 | Sale | −2,060 | $9.97 | $20.54K | 1,047,942 |
| Glazer Capital, Llc 10% owner | Feb 22, 2021 | Sale | −698 | $10.50 | $7.33K | 1,050,002 |
| Glazer Capital, Llc 10% owner | Feb 19, 2021 | Sale | −2,112 | $10.50 | $22.18K | 1,050,700 |
| Glazer Capital, Llc 10% owner | Feb 18, 2021 | Sale | −10,000 | $10.45 | $104.50K | 1,052,812 |
| Glazer Capital, Llc 10% owner | Feb 5, 2021 | Sale | −212 | $10.40 | $2.20K | 1,062,812 |
| Glazer Capital, Llc 10% owner | Jan 14, 2021 | Sale | −101 | $10.40 | $1.05K | 1,063,024 |
| Glazer Capital, Llc 10% owner | Jan 8, 2021 | Sale | −10,000 | $10.25 | $102.50K | 1,063,125 |
| Glazer Capital, Llc 10% owner | Dec 30, 2020 | Sale | −75 | $10.25 | $769 | 1,073,125 |
| Glazer Capital, Llc 10% owner | Dec 29, 2020 | Sale | −18 | $10.25 | $185 | 1,073,200 |
| Glazer Capital, Llc 10% owner | Dec 28, 2020 | Sale | −10,000 | $10.20 | $102.00K | 1,073,218 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Singh Mahal Jeetinder Executive Officer | Dec 12, 2024 | 900 | $20.22K | Dec 12, 2024 | Exercise of Stock Options Granted on 6/1/2020 |
| Singh Mahal Jeetinder Executive Officer | Sep 12, 2024 | 900 | $18.59K | Sep 12, 2024 | Exercise of Stock Options Granted on 6/1/2020 |
| Singh Mahal Jeetinder Executive Officer | Jun 12, 2024 | 900 | $21.59K | Jun 12, 2024 | Exercise of Stock Options Granted on 6/1/2020 |
| Singh Mahal Jeetinder Executive Officer | Mar 12, 2024 | 900 | $23.87K | Mar 12, 2024 | Exercise of Stock Options Granted on 6/1/2020 |
| William Lis Director | Mar 6, 2024 | 16,000 | $336.48K | Mar 6, 2024 | STOCK OPTION EXERCISE |
| Lis William Director | Oct 13, 2023 | 7,965 | $6.77K | Oct 13, 2023 | Restricted Stock Unit Vesting |
| Singh Mahal Jeetinder Executive Officer | Jun 13, 2023 | 9,000 | $204.12K | Jun 13, 2023 | Exercise of Stock Options Granted on 06/01/2020 |
| Anna Louise French Director | Apr 14, 2023 | 7,000 | $10.36K | Apr 14, 2023 | RESTRICTED STOCK |
| Kurt Von Emster Officer | Apr 13, 2023 | 9,075 | $13.52K | Apr 13, 2023 | RESTICTED STOCK |
| William Lis Director | Apr 13, 2023 | 8,500 | $12.24K | Apr 13, 2023 | RESTRICTED STOCK |